UK pharma manufacturing output increased last year according to EEF, which says lower costs and a legacy of R&D investment will drive further growth in 2016.
Despite Sanofi’s “conflicted” management and subsequent abandonment of Afrezza, the market opportunity for inhaled insulin is still huge, according to Dance Biopharm's CEO.
Data falsification at API facilities is getting harder to spot say regulators who have called for more systems training and international collaboration.
New acquisition Sigma Aldrich will play a part in African growth plans in addition to giving it a presence in the preclinical services sector says Merck*.
A manganese-based catalyst invented by chemists in Illinois could transform the solubility of drug candidates and improve their therapeutic properties.
Pollution caused by pharmaceuticals in wastewater is a major challenge facing the industry, but researchers in Greece may have come up with a solution.
A team of researchers has modified a lectin protein found in bananas to diminish its inflammatory properties, potentially setting it on the path to use as an antiviral.
EMD Millipore will offer drugmakers two-years of unlimited access to its suite of raw materials dossiers for 20,000€ as part of its enhanced portfolio offering.
Big Pharma has returned to Europe for its API sourcing due to reasons of quality and reliability, according to the European Fine Chemicals Group (EFCG).
Nisso Soda Co. has partnered with Mutchler Pharmaceutical Ingredients to try and win a greater share of the US hydroxypropyl cellulose market months after expanding production capacity.
Innovate Pharmaceuticals has launched what it claims is the world’s first shelf-stable liquid aspirin, and says it is on the look-out for a licensing partner for the “$500m” market.
Increasing QbD needs and a range of technical service centres have driven up the prices of Evonik’s drug delivery excipient portfolio, the company says.
The EU needs to better define mercury limits for drugs and dietary supplements say Polish researchers who want pharmaceuticals in Europe to be tested more regularly.
The National Institute of Pharmaceutical Education and Research (NIPER) in India has created and licensed technology for producing nano-crystal based medicines that it says will cut drug costs.
Novo Nordisk has confirmed it will build an API plant in the US, telling this publication a desire to have manufacturing capacity in the key market for its oral diabetes candidate, semaglutide, drove the decision.
Royal DSM will make up to 1100 staff redundant by the end of 2017 to cut costs following the formation of its Sinochem JV and pharma products deal with Patheon.
Manufacturers of excipients are being sent inappropriate requests for stability data by some regulators and pharma companies, threatening to disrupt the supply chain, IPEC claims.
GlaxoSmithKline was forced to briefly shutter its Zebulon, NC, manufacturing facility after the company discovered legionella bacteria in one of its cooling towers.
IPEC Europe has reminded drugmakers they have less than a year to risk assess all excipients used in their products under recently introduced EU rules.
As part of a push to bring more novel excipients to market, IPEC-Americas is calling on the FDA to create a new regulatory review process that could relieve some of the uncertainty around the use of new excipients.
AMRI has bought Spanish contractor Gadea Pharmaceutical Group for $174m (€160m) to add muscle to its steroid API business and sign up more customers outside the US.
Even if claims about Kumdang-2 are real, access to the drug and other pharmaceuticals in North Korea is limited to those who can pay black market prices according to a UK-based defector.
Toronto-based Attix Pharmaceuticals has received a US FDA warning letter after an inspection from November and a lack of corrective actions in the company’s response to the FDA.
Generic pills are a safety risk if they are too different from their reference drug according to the US FDA, which wants developers to consider physical characteristics when making copycat meds.
A capsule inspired by the porous structure of seashells has been developed to protect drugs from extreme temperatures and could be used in controlled delivery.
European drug industry groups have contrasted 'misguided' cuts to the Horizon 2020 budget with US plans to increase NIH funding for science R&D under the 21st Century Cures Bill.
Multinational excipient-makers will drive US interest in EXCiPACT, the industry-led certification scheme says as a UK Colorcon plant becomes the eighteenth site to receive accreditation.
US production of chemicals for the drug industry fell in April according to data released days after renewed calls for permanent tax breaks to help American manufacturers compete globally.